| |
| Chemotherapy Protocols |
| |
|
| |
| Protocol |
BEP |
| Cancer |
Testicular Cancer |
| Reference |
Einhorm1 |
| |
|
|
| BEP |
Bleomycin |
30 U bolus, once a week |
| |
Etoposide |
100 mg/m² over 30 min., day 1-5 |
| |
Cisplatin |
20 mg/m² over 30 min., day 1-5 |
| |
|
|
| |
3-week cycle, 3-4 cycles |
|
|
| |
| Protocol |
VIP |
| Cancer |
Recurrent Testicular Cancer |
| Reference |
Harstrick2 |
| |
|
|
| VIP |
etoposide |
100 mg/m² over 1 hr, day 1-5 |
| |
ifosfamide |
1.2 g/m² over 1 hr, day 1-5 |
| |
cisplatin |
20 mg/m² over 1 hr, day 1-5 |
| |
|
|
| |
every 3-4 weeks, maximal 4 cycles |
|
|
| |
| Protocol |
PaP |
| Cancer |
Ovarian Cancer |
| Reference |
Muggia3 |
| |
|
|
| PaP |
paclitaxel |
135 mg/m² over 24 h, day 1 |
| |
cisplatin |
75 mg/m² , day 2 |
| |
|
|
| |
every 3 weeks, 6 cycles |
|
|
| |
| Protocol |
M-VAC |
| Cancer |
Transitional Cell Cancer of Urothelium |
| Reference |
Sternberg4 |
| |
|
|
| M-VAC |
methotrexate |
30 mg/m², day 1, 15, 22 |
| |
vinblastine |
3 mg/m², day 2, 15, 22 |
| |
doxorubicin |
30 mg/m², day 2 |
| |
cisplatin |
70 mg/m², day 2 |
| |
|
|
| |
every 4 weeks, 4 to 7 cycles |
|
|
| |
| Protocol |
EP |
| Cancer |
Non Small Cell Lung Cancer |
| Reference |
Klastersky5 |
| |
|
|
| EP |
etoposide |
100 mg/m² over 60 min., day 1-3 |
| |
cisplatin |
120 mg/m² over 20 min., day 1 |
| |
|
|
| |
every 3-4 weeks, minimal 3 cycles |
|
|
| |
| Protocol |
PaP |
| Cancer |
Non Small Cell Lung Cancer |
| Reference |
Giaccone6 |
| |
|
|
| PaP |
paclitaxel |
175 mg/m² over 3 hrs, day 1 |
| |
cisplatin |
80 mg/m² day 1 |
| |
|
|
| |
every 3 weeks, 6 cycles |
|
|
| |
| Protocol |
GP |
| Cancer |
Non Small Cell Lung Cancer |
| Reference |
Sandler7 |
| |
|
|
| GP |
gemcitabine |
1 g/m² over 30-60 min., days 1, 8, 15 |
| |
cisplatin |
100 mg/m² over 30-120 min., day 1 |
| |
|
|
| |
every 4 weeks, maximal 6 cycles |
|
|
| |
| Protocol |
CF |
| Cancer |
Head and Neck Cancer |
| Reference |
Forastiere8 |
| |
|
|
| CF |
cisplatin |
100 mg/m² over 15-30 min., day 1 |
| |
5-FU |
1 g/m²/day, 96-hr continuous infusion |
| |
|
|
| |
every 3 weeks, median 4 cycles |
|
|
| |
| References: |
|
| 1. Einhorn et al., J. Clin. Oncol. 7 (1989) 387-91. |
| 2. Harstrick et al., J. Clin. Oncol. 9 (1991) 1549-55. |
| 3. Muggia et al., J. Clin. Oncol. 18 (2000) 106-15. |
| 4. Sternberg et al., J. Urol., 139 (1988) 461-9. |
| 5. Klastersky et al., J. Clin. Oncol., 8 (1990) 1556-62. |
| 6. Giaccone et al., J. Clin. Oncol. 16 (1998) 2133-41. |
| 7. Sandler et al., J. Clin. Oncol. 18 (2000) 122-30. |
| 8. Forastiere et al., J. Clin. Oncol. 10 (1992) 1245-51. |
|
| |
|
